Compare TNET & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | SUPN |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2000 | 2010 |
| Metric | TNET | SUPN |
|---|---|---|
| Price | $62.41 | $42.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $66.20 | $61.75 |
| AVG Volume (30 Days) | 251.2K | ★ 566.5K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | $392,755,000.00 |
| Revenue This Year | N/A | $23.21 |
| Revenue Next Year | $3.80 | $54.85 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.67 | $40.51 |
| 52 Week High | $73.08 | $59.68 |
| Indicator | TNET | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 45.35 |
| Support Level | $59.61 | $42.54 |
| Resistance Level | $64.37 | $52.33 |
| Average True Range (ATR) | 1.87 | 1.40 |
| MACD | -0.44 | 0.12 |
| Stochastic Oscillator | 8.54 | 44.81 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.